CD68 and lung cancer: DSP studies showed that higher lymphoid infiltrates and T-cell clonality in the TME were associated with improved IC efficacy (66, 67); CD66b expression in the CD45+CD68 molecular compartment was linked to IO therapy resistance in lung cancers (28); B2M and CD25 levels in tumour and CD11c in stroma were correlated with prolonged survival in head and neck SCC (29).